Civilization Ventures is a venture capital firm focused on cutting edge innovations in exponential health tech and biology.
Key people at Civilization Ventures.
# Civilization Ventures: Pioneering the Future of Health Tech and Biology
Civilization Ventures is a San Francisco-based venture capital firm that has established itself as a leading investor in breakthrough healthcare technologies and life sciences innovations[1][2]. Founded in 2017, the firm manages over $100 million in capital and has invested in more than 60 companies, with a portfolio spanning genomics, diagnostics, digital health, synthetic biology, and gene therapies[1][2]. The firm's mission centers on backing scientific founders who are developing disruptive innovations that advance human longevity and reshape the future of healthcare through a founder-centric, operator-led investment approach[1][5].
Civilization Ventures operates with a clear mission: to support visionary scientific founders in developing cutting-edge innovations that address critical opportunities in health tech and biology[3]. The firm's investment philosophy is rooted in what they call a "founder-first" approach, inspired by the operational experience of their leadership team and grounded in humility, empathy, and deep scientific expertise[6]. Rather than taking a purely financial approach, Civilization Ventures functions as an operator-led fund that provides not just capital but active mentorship and strategic guidance to help entrepreneurs succeed[5].
The firm's thematic focus spans four primary areas: genomics and diagnostics, digital health, synthetic biology (including gene and cell therapies), and artificial intelligence applied to healthcare[1][3][6]. This concentrated focus allows the firm to develop deep expertise and meaningful networks within these high-impact domains. The investment thesis emphasizes preventative, personalized, and regenerative healthcare solutions that can meaningfully improve patient outcomes and address large-scale health challenges[2].
Civilization Ventures has become a significant force in the healthcare venture capital landscape, not merely through capital deployment but through its unique fellowship program that trains PhDs to become entrepreneurs and future life sciences leaders[1]. The firm's extensive network of industry experts, academics, and clinicians provides portfolio companies with access to resources and expertise that extend far beyond traditional venture funding[1]. With nine successful exits to date—including notable acquisitions and public listings—the firm has demonstrated a proven ability to scale companies from early stages to meaningful exits[5].
Civilization Ventures was founded in 2017 by Shahram Seyedin-Noor, a seasoned operator with over 25 years of experience in life sciences and venture capital[5]. Seyedin-Noor brought substantial operational credentials to the venture world, having co-founded and run Inspirna (which has two oncology drugs in clinical trials) and helped run NextBio, a bioinformatics company that was acquired by Illumina[5]. The firm launched with a modest $1 million pilot fund focused on backing innovators in genomics, diagnostics, digital health, and synthetic biology[4].
The firm's evolution reflects both market timing and strategic capital raises. In 2020, as the world grappled with the COVID-19 pandemic, Civilization Ventures raised its $35 million second fund to lead pre-seed and seed investments[4]. This was followed by an Opportunity Fund that brought total capital under management to over $100 million, positioning the firm to support founders as they scaled beyond early stages[4]. The firm operates with a lean, three-person team structure that emphasizes deep operational involvement rather than sprawling infrastructure[5].
Unlike traditional venture firms staffed primarily by investors, Civilization Ventures is built by operators who have founded, run, and scaled life sciences companies. This operational pedigree translates into meaningful support for founders beyond capital—the team provides strategic guidance, operational mentorship, and access to their networks of biopharma executives and life sciences leaders[1][5].
The firm's philosophy prioritizes founder success through humility and empathy rather than top-down control[6]. This manifests in several ways: mentorship and strategic guidance tailored to each founder's needs, a unique fellowship program that develops the next generation of life sciences entrepreneurs, and networking opportunities that connect founders with industry experts, academics, and clinicians[1].
By focusing exclusively on biology and healthcare rather than diversifying across multiple sectors, Civilization Ventures has built deep domain expertise and a robust network within life sciences[5]. This concentration allows the firm to identify trends early—such as the emergence of liquid biopsy technologies and AI-driven diagnostics—and position portfolio companies at the forefront of innovation[6].
The firm's portfolio includes category-defining companies with significant exits. Rocket Pharma became a Nasdaq-listed unicorn with multiple first-in-class gene therapies in clinical trials[4]. Lemonaid Health was acquired by 23andMe in a landmark $400 million deal[4]. Rewrite Therapeutics, a gene editing pioneer, was acquired by Intellia for $200 million[4]. Fluent BioSciences was acquired by Illumina, and Omada Health completed a public listing as a seminal event for the health tech sector[4]. These exits demonstrate the firm's ability to identify and nurture companies with genuine market potential and transformative impact.
Civilization Ventures operates at the intersection of several powerful macro trends reshaping healthcare and life sciences. The firm is riding the wave of genomics democratization, where sequencing costs have plummeted and genetic information is becoming increasingly accessible and actionable[5]. Simultaneously, the firm is positioned to benefit from the AI revolution in healthcare, where machine learning is enabling earlier disease detection, more accurate diagnostics, and personalized treatment approaches[5].
The timing is particularly favorable for the firm's focus areas. Gene and cell therapies represent one of the most promising frontiers in medicine, with the potential to cure previously untreatable genetic diseases[4]. Digital health has transitioned from a niche category to mainstream adoption, accelerated by the COVID-19 pandemic and changing consumer expectations around healthcare delivery[4]. Liquid biopsy technologies—which detect disease markers from blood samples—are revolutionizing early cancer detection and prenatal screening, addressing massive unmet needs in preventative medicine[6].
Civilization Ventures influences the broader ecosystem by demonstrating that specialized, operator-led venture firms can compete effectively with larger, generalist funds. The firm's success validates the thesis that deep domain expertise, founder-centric support, and operational involvement create superior outcomes. Additionally, through its fellowship program and mentorship activities, the firm is actively shaping the next generation of life sciences entrepreneurs and investors, multiplying its impact beyond direct portfolio returns.
Civilization Ventures stands at an inflection point in healthcare innovation. The firm has proven its ability to identify and nurture transformative companies across genomics, diagnostics, digital health, and synthetic biology. With over $100 million under management and a track record of meaningful exits, the firm has established credibility as a leading player in healthcare venture capital.
Looking forward, several trends will likely shape Civilization Ventures' trajectory. The convergence of genomics, AI, and diagnostics will create unprecedented opportunities to detect and prevent disease earlier in the disease progression curve. Regulatory tailwinds for gene therapies and digital health solutions will accelerate commercialization timelines for portfolio companies. The shift toward value-based care and outcomes-driven healthcare will favor the firm's portfolio companies that are building solutions to manage chronic diseases and improve population health.
The firm's greatest competitive advantage—its operator-led model and founder-centric philosophy—will become increasingly valuable as the venture landscape becomes more crowded and capital becomes more abundant. In an environment where capital is plentiful but operational expertise is scarce, Civilization Ventures' ability to provide both capital and meaningful support positions it to attract the most ambitious scientific founders and generate outsized returns. As healthcare continues its transformation from reactive treatment to proactive prevention and personalization, Civilization Ventures is well-positioned to fund the companies that will define this new era.
Key people at Civilization Ventures.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2024 | Foresight Diagnostics | $33.0M Series B | — | Foresite Capital |
| Apr 1, 2023 | Foresight Diagnostics | $59.0M Series B | — | Foresite Capital |
| Feb 1, 2023 | Wyndly | $2.0M Seed | — | Antler, Blackhorn Ventures, Immeasurable, Neotribe Ventures, SNR, Y Combinator |
| Mar 1, 2021 | Seer | $2.0M Seed | — | 468 Capital, Antler, DX Ventures, E14 Fund, Foundation Capital, Global Founders Capital, Immeasurable, SNR, White Star Capital, Y Combinator, Cornelius Boersch, Jean Pigozzi |
| Dec 1, 2020 | Foresight Diagnostics | $13.0M Series A | — | Foresite Capital |
